 After data readout from KRAS drug adagrasib in colon cancer, Mirati Therapeutics Inc NASDAQ: MRTX has announced positive topline results from a Phase II cohort of its KRYSTAL-1 study of adagrasib in non-small cell lung cancer NSCLC. Adagrasib posted a response rate of 43 in second-line-or-later patients with metastatic NSCLC containing a KRAS-G12C mutation. 